Publications by authors named "Alexis B Cortot"

Claim this Profile
E
Efficacy of Neratinib-Based Therapy in ERBB2-Mutant Lung Adenocarcinomas: Findings From 2 International Phase 2 Studies.
Bob T Li, Leena Gandhi, Vignesh Ravichandran, Benjamin Besse, Julien Mazières, Alexis B Cortot

Clin Lung Cancer· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: Patient satisfaction and resource utilization results from the PALOMA-3 study.
Mariam Alexander, Ying Cheng, Se-Hoon Lee, Antonio Passaro, Alexander I Spira, Alexis B Cortot

Eur J Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COMPOSIT study: evaluating osimertinib combination with targeted therapies in EGFR-mutated non-small cell lung cancer.
Camille Mehlman, Aurelie Swalduz, Isabelle Monnet, Clara Morin, Marie Wislez, Alexis B Cortot

Oncologist· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MET variants with activating N-lobe mutations identified in hereditary papillary renal cell carcinomas still require ligand stimulation.
Célia Guérin, Audrey Vinchent, Marie Fernandes, Isabelle Damour, Agathe Laratte, Alexis B Cortot

Mol Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prolonging lung cancer response to EGFR inhibition by targeting the selective advantage of resistant cells.
Lisa Brunet, David Alexandre, Jiyoung Lee, Maria Del Mar Blanquer-Rosselló, David Bracquemond, Alexis B Cortot

Nat Commun· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with MET Rearrangements.
Seshiru Nakazawa, Federica Pecci, Igor Odintsov, Dimitris Gazgalis, Felix H Gottlieb, Alexis B Cortot

Cancer Discov· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plain language summary of MARIPOSA-2: amivantamab-chemotherapy either with or without lazertinib for treatment of non-small-cell lung cancer.
Antonio Passaro, Alexis B Cortot, Ryan D Gentzler, Karen L Reckamp, Sujay Shah

Future Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MET variants with activating N-lobe mutations identified in hereditary papillary renal cell carcinomas still require ligand stimulation.
Célia Guérin, Audrey Vinchent, Marie Fernandes, Isabelle Damour, Agathe Laratte, Alexis B Cortot

bioRxiv· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MOMENT registry: Patients with advanced non-small-cell lung cancer harboring exon 14 skipping treated with systemic therapy.
Michael Thomas, Petros Christopoulos, Wade T Iams, Julien Mazières, Alexis B Cortot

J Comp Eff Res· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patterns of Treatment and Real-World Outcomes of Patients With Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations Receiving Mobocertinib: The EXTRACT Study.
Geoffrey Liu, Shi Feng Nyaw, Tony S K Mok, Hubert Curcio, Alexis B Cortot

Cancer Med· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Capmatinib efficacy for METex14 non-small cell lung cancer patients: Results of the IFCT-2104 CAPMATU study.
Marion Ferreira, Aurélie Swalduz, Laurent Greillier, Pauline du Rusquec, Hubert Curcio, Alexis B Cortot

Lung Cancer· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
strain EXL01 boosts efficacy of immune checkpoint inhibitors.
Marius Bredon, Camille Danne, Hang Phuong Pham, Pauline Ruffié, Alban Bessede, Alexis B Cortot

Oncoimmunology· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of 164 patients with NRAS mutated non-small cell lung cancer (NSCLC).
Agathe Dehem, Julien Mazieres, Ali Chour, Florian Guisier, Marion Ferreira, Alexis B Cortot

Lung Cancer· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MET exon 14 skipping mutation is a hepatocyte growth factor (HGF)-dependent oncogenic driver in vitro and in humanised HGF knock-in mice.
Marie Fernandes, Brynna Hoggard, Philippe Jamme, Sonia Paget, Marie-José Truong, Alexis B Cortot

Mol Oncol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Histo-Molecular Factors of Response to Combined Chemotherapy and Immunotherapy in Non-Small Cell Lung Cancers.
Marine Marchal, Vincent Leroy, Hélène Behal, Eric Dansin, Nicolas Paris, Alexis B Cortot

Target Oncol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial.
Julien Mazieres, Paul K Paik, Marina C Garassino, Xiuning Le, Hiroshi Sakai, Alexis B Cortot

JAMA Oncol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and Outcomes.
Julien Mazieres, Helene Vioix, Boris M Pfeiffer, Rhiannon I Campden, Zhiyuan Chen, Alexis B Cortot

Clin Lung Cancer· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transforming properties of MET receptor exon 14 skipping can be recapitulated by loss of the CBL ubiquitin ligase binding site.
Marie Fernandes, Sonia Paget, Zoulika Kherrouche, Marie-José Truong, Audrey Vinchent, Alexis B Cortot

FEBS Lett· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to Capmatinib in a MET Fusion-positive Cholangiocarcinoma.
Anthony Turpin, Clotilde Descarpentries, Valérie Grégoire, Olivier Farchi, Alexis B Cortot

Oncologist· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brief Report: First-line Pembrolizumab in Metastatic Non-Small Cell Lung Cancer Habouring MET Exon 14 Skipping Mutation and PD-L1 ≥50% (GFPC 01-20 Study).
Florian Guisier, Renaud Descourt, Helene Babey, Eric Huchot, Lionel Falchero, Alexis B Cortot

Clin Lung Cancer· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PD-1/PD-L1 inhibitor activity in patients with gene-rearrangement positive non-small cell lung cancer-an IMMUNOTARGET case series.
Rao Mushtaq, Alexis B Cortot, Oliver Gautschi, Julien Mazieres, D Ross Camidge

Transl Lung Cancer Res· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management.
Remi Veillon, Hiroshi Sakai, Xiuning Le, Enriqueta Felip, Alexis B Cortot

Clin Lung Cancer· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Paclitaxel-bevacizumab combination in advanced non-squamous non-small-cell lung cancer (NSCLC): AVATAX, a retrospective multicentric study.
Geoffroy Bilger, Anne-Claire Toffart, Marie Darrason, Michaël Duruisseaux, Lucie Ulmer, Alexis B Cortot

Ther Adv Med Oncol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort.
Simon Baldacci, Benjamin Besse, Virginie Avrillon, Bertrand Mennecier, Julien Mazieres, Alexis B Cortot

Eur J Cancer· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study.
Renaud Descourt, Maurice Pérol, Gaëlle Rousseau-Bussac, David Planchard, Bertrand Mennecier, Alexis Benjamin Cortot

Cancers (Basel)· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis